Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company, has posted a more than two-fold growth in net profit for the second quarter ended September 30, 2012, to Rs 6.49 crore as against Rs 2.56 crore in the same quarter last year, registering a 153.51 per cent growth.
During the second quarter, the company has reported 4.79 per cent growth in revenue to Rs 50.3 crore, as compared to Rs 48 crore in the corresponding quarter last year, according to a company release.
Currently, Suven has a patent portfolio of 18 inventions, 541 product patents and 36 process patents. Its product profile has 13 molecule including one molecule has completed the phase -1 trial and currently is in the process of moving into the phase 2a, proof of concept study, the release said.
The company's scrip has last traded at Rs 28.25 on the Bombay Stock Exchange on Tuesday.
